Skip to main content

Table 1 Patient characteristics

From: Expansion of antibody secreting cells and modulation of neutralizing antibody activity in HIV infected individuals undergoing structured treatment interruptions

Patient Id

Age (years)

Sexa

Years since diagnosis

Baseline VLc(RNA copies/ml)

Baseline CD4 cell count (cells/mm3)

Baseline CD8 cell count (cells/mm3)

Baseline treatmentb

IL-2 administration

1

42

F

5

80

1327

1225

D4T + 3TC + NFV

NO

2

54

M

12

33

801

763

D4T + 3TC + NFV

NO

3

39

M

2

50

580

548

DDI + 3TC + NFV

NO

4

34

M

15

1200

672

819

ABV + DDI + EFV

NO

5

41

F

8

20

2702

1061

3TC + NFV + AZT

NO

6

45

F

7

20

1548

1380

DDI + D4T + NFV

YES

7

51

F

16

20

956

697

D4T + IDV + 3TC + RTV

YES

8

55

M

4

20

801

744

D4T,3TC,NFV

YES

9

61

M

5

20

1122

570

IDV + 3TC + AZT

YES

10

51

M

9

20

987

810

EFV + D4T + 3TC

YES

  1. aM: male; F: female.
  2. bD4T: Stavudine; 3TC:Lamivudine; NFV: Nelfinavir; DDI: Didanosine; ABV: Abacavir; EFV: Efavirenz; AZT: Zidovudina; IDV: Indinavir; RTV: Ritonavir.
  3. c In patient 4 VL value at baseline of 1200 correspond to a blip in viral load as, both prior and post values are < 20.